EVIDENCE WATCH
A review and assessment of recent clinical trial data

Inflammatory breast cancer
A PHASE II COMBINATION STUDY OF LAPATINIB AND PACLITAXEL AS A NEOADJUVANT THERAPY IN PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BREAST CANCER (IBC). SABCS 2006, ABSTRACT 1.

Metastatic breast cancer
LAPATINIB PLUS CAPECITABINE SHOWS SUPERIOR EFFICACY COMPARED TO CAPECITABINE ALONE IN PATIENTS WITH ERBB2 POSITIVE ADVANCED OR METASTATIC BREAST CANCER INITIAL BIOMARKER DATA. SABCS 2006, ABSTRACT 2.

Diffuse large B cell lymphoma
ADDITION OF RITUXIMAB (R) TO CHOP IMPROVES SURVIVAL IN THE NON-GCB SUBTYPE OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). ASH 2006, ABSTRACT 816.

STRONG P53 EXPRESSION IS AN INDEPENDENT PREDICTOR OF OUTCOME IN DE NOVO DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) TREATED WITH EITHER CHOP OR CHOP-R. ASH 2006, ABSTRACT 812.

 

To view the clinical trial data of the above topics click here (pdf format)

 
Back to Top of Page 

 

 
 
 
Oncology Exchange continues overviews of important clinical trial data presented at the 29th San Antonio Breast Cancer Symposium (SABCS), held December 14–17, 2006 and at the 48th Annual Meeting of the American Society of Hematology (ASH), held December 8–11, 2006 in Atlanta, Georgia. Leading Canadian experts offer commentary and clinical interpretations.
 

 

 
© Parkhurst Publishing Privacy Statement
Legal Terms of Use
 Site created by Spin Design (514) 995-4398